Please, Come Back! | GenomeWeb

Please, Come Back!

Pharmalot's Ed Silverman wonders how pharmaceutical companies will deal with the impending "patent cliffs" they face that will leave them with no patent protection on their most popular drugs. One idea, he says, is to create an atmosphere of customer loyalty, emulating companies like Apple or Starbucks. Writing in BusinessWeek, consultants G.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.